wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Kearns NOT DRUGS and DRUGS of pp pt 2

Total questions: 62

Worksheet time: 34mins

Name
Class
Date
1.

Which of the following are used in chronic myelogenous leukemia (CML)?

a)

BCR-ABL inhibitors

b)

BRAF inhibitors

c)

Mitogen-Activated Extracellular Kinase (MEK) 1 and 2 inhibitors

d)

Epidermal Growth Factor Receptor (EGFR) inhibitors

e)

Anaplastic Lymphoma Kinase (ALK) inhibitors

2.

Which of the following are used in melanoma?

a)

BCR-ABL inhibitors

b)

BRAF inhibitors

c)

Mitogen-Activated Extracellular Kinase (MEK) 1 and 2 inhibitors

d)

Epidermal Growth Factor Receptor (EGFR) inhibitors

e)

Anaplastic Lymphoma Kinase (ALK) inhibitors

3.

Which of the following are used in non-small cell lung cancer (NSCLC)?

a)

BCR-ABL inhibitors

b)

BRAF inhibitors

c)

Mitogen-Activated Extracellular Kinase (MEK) 1 and 2 inhibitors

d)

Epidermal Growth Factor Receptor (EGFR) inhibitors

e)

Anaplastic Lymphoma Kinase (ALK) inhibitors

4.

Tyrosine kinase inhibitors are targeted small-molecule anticancer drugs

a)

true

b)

false

5.

"- tin" stands for:

a)

tyrosine kinase inhibitors

b)

proteasome inhibitors

c)

cyclin-dependent kinase inhibitors

6.

"- zom" stands for:

a)

tyrosine kinase inhibitors

b)

proteasome inhibitors

c)

cyclin-dependent kinase inhibitors

7.

"- cicli" stands for:

a)

tyrosine kinase inhibitors

b)

proteasome inhibitors

c)

cyclin-dependent kinase inhibitors

8.

Which of the following are part of the new BCR-ABL targeted therapy?

a)

HQP1351

b)

PF-114

c)

KQ105

d)

K0706

e)

104.7

9.

Which of the following are TKIs approved for Chronic Myelogenous leukemia (CML)?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

10.

Which of the following is used for the myristoyl pocket of the kinase domain of the TK transmembrane protein?

a)

imatinib

b)

asciminib

c)

nilotinib

d)

bosutinib

e)

ponatinib

11.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) is an oral molecule TKI inhibitor that treats Ph+ CML?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

12.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) is an antagonist to phosphorylation, so produces apoptosis?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

13.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) has hepatotoxicity, hemorrhage, GI perforation and dermatologic reactions as warning?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

14.

Imatinib will competitively inhibit the metabolism of drugs that are inhibitors or inducers of ________ substrates leading to changes in plasma concentrations of imatinib or coadministered drugs

a)

CYP2D6

b)

CYP3A4

c)

CYP17A1

d)

CYP19A1

15.

Which of the following TKIs approved for Chronic Myelogenous leukemia (CML) is a second generation TKI indicated for newly diagnosed Ph+ CML TKI resistant to prior treatment with imatinib?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

16.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) prolongs QT interval?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

17.

In which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML), CYP3A4 inhibitors should be avoided?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

18.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) is an orally bioavailable multitargeted TKI?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

19.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) has an antiangiogenic and antineoplastic mechanism of action?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

20.

Which of the following TKIs that are approved for Chronic Myelogenous leukemia (CML) is used as/for third generation pan-mutations?

a)

imatinib

b)

dasatinib

c)

nilotinib

d)

bosutinib

e)

ponatinib

21.

Ponatinib is a tyrosine kinase inhibitor approved for CML, known to be a third generation TKI, and it is used to treat specifically which of the following?

a)

acute lymphoblastic leukemia Ph+/T3151 mutation

b)

newly diagnosed Ph+ CML TKI resistant to prior treatment with imatinib

c)

Ph+ CML

d)

used when other TKIs cannot be used

22.

T351 is a drug therapy-resistant missense mutation of BCR-ABL

a)

true

b)

false

23.

During the EGFR pathway, Osirmetinib inhibits phosphorylation internally

a)

true

b)

false

24.

During the EGFR pathway which is initiated by binding of extracellular ligand, RAS/MAPK leads to:

a)

activation of transcription factors

b)

growth, proliferation, angiogenesis

25.

During the EGFR pathway which is initiated by binding of extracellular ligand, PIP3K leads to:

a)

activation of transcription factors

b)

growth, proliferation, angiogenesis

26.

EGFR tyrosine kinase inhibitors can cause diarrhea and acneiform rash in:

a)

30% of patients

b)

50% of patients

c)

20% of patients

d)

75% of patients

27.

Erlotinib is an EGFR tyrosine kinase inhibitor that causes a serious or fatal interstitial disease in which of the following?

a)

lung

b)

kidney

c)

heart

d)

GI

28.

Which of the following is a VEGF inhibitor?

a)

sunitinib

b)

nilotinib

c)

bortezomib

d)

palbociclib

29.

Which of the following has a warning for severe, potentially fatal hepatotoxicity?

a)

sunitinib

b)

nilotinib

c)

bortezomib

d)

palbociclib

30.

Which of the following competitively inhibits the binding of ATP to TK domain on the VEGF receptor?

a)

sunitinib

b)

nilotinib

c)

bortezomib

d)

palbociclib

31.

EGFR and VGFR-2 signaling can both trigger PI3K/AKT/ and RAS/RAF/ERK pathways

a)

true

b)

false

32.

Therapeutic agents are developed to inhibit EGFR and VGFR pathways

a)

true

b)

false

33.

Which of the following is the monoclonal antibodies interfering with the EXTRACELLULAR domain of VEGFR-2?

a)

bevacizumab

b)

nintedanib

c)

axitinib

d)

cediranib

e)

ramucirumab

34.

Which of the following is the monoclonal antibodies interfering or inhibiting the VEGF-A protein in the EXTRACELLULAR domain?

a)

bevacizumab

b)

nintedanib

c)

axitinib

d)

cediranib

e)

ramucirumab

35.

Which of the following small molecules inhibitors for EGFR interfering with the pathway are first generation?

a)

erlotinib

b)

geftinib

c)

afatinib

d)

dacomitinib

e)

osimertinib

36.

Which of the following small molecules inhibitors for EGFR interfering with the pathway are second generation?

a)

erlotinib

b)

geftinib

c)

afatinib

d)

dacomitinib

e)

osimertinib

37.

Which of the following small molecules inhibitors for EGFR interfering with the pathway are third generation?

a)

erlotinib

b)

geftinib

c)

afatinib

d)

dacomitinib

e)

osimertinib

38.

The UPP is responsible for extracellular protein degradation in all eukaryotic cells

a)

true

b)

false

39.

Malignant cells are addicted to the UPP pathway for survival

a)

true

b)

false

40.

The proteasome removes damaged and short-lived regulatory proteins from the cell that would otherwise accumulate and induce cell death or impair cellular function

a)

true

b)

false

41.

Upregulation of the UPP has been linked to:

a)

cancer

b)

neurodegenerative diseases such as Alzheimer's disease

42.

Downregulation of the UPP has been linked to:

a)

cancer

b)

neurodegenerative diseases such as Alzheimer's disease

43.

The utilization of which of the following can result in a decrease of anti-apoptotic factors and inflammatory molecules; cell adhesion?

a)

proteasome inhibitors

b)

cyclin-D kinase inhibitors

c)

histone deacetylase inhibitors

44.

Which of the following proteasome inhibitors was the first one approved by the FDA?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

45.

Which of the following proteasome inhibitors has a modified dipeptide boronic acid inhibitor that inhibits 26S proteasome as mechanism of action?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

46.

Bortezomib is a proteasome inhibitor with kinetics of deboronization and hydroxylation by:

a)

CYP3A4

b)

CYP2D6

c)

CYP2C19

d)

CYP17A

47.

Bind cyclins to form CDK-cyclin complex

a)

proteasome inhibitors

b)

cyclin-D kinase inhibitors

c)

histone deacetylase inhibitors

48.

CDK-cyclin kinase activity drives progression through the cell cycle, inhibition therefore restricts cell cycle progression

a)

true

b)

false

49.

The most prevalent cyclin in G1 phase is:

a)

cyclin E

b)

cyclin B

c)

cyclin D

50.

Which of the following is a cyclin-dependent kinase inhibitor?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

51.

Which of the following is a potent, selective inhibitor of CDK4 and CDK 6?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

52.

Palbociclib is a cyclin-dependent kinase inhibitor that blocks phosphorylation of retinoblastoma (RB) tumor suppressor protein and causes arrest on which of the following phases?

a)

G0

b)

G1

c)

G2

d)

M

53.

Which of the following is used for relapsed or refractory multiple myeloma?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

54.

Which of the following is used orally for some forms of breast cancer?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

55.

Initially studied for neurology and psychiatry, so they have mood stabilizer and anti epileptic effects

a)

proteasome inhibitors

b)

cyclin-D kinase inhibitors

c)

histone deacetylase inhibitors

56.

Which of the following can decrease inhibition of tumor suppressor gene expression?

a)

proteasome inhibitors

b)

cyclin-D kinase inhibitors

c)

histone deacetylase inhibitors

57.

Which of the following is a histone deacetylase inhibitor that can be oral administered?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

58.

Which of the following has a hepatic metabolism?

a)

bortezomib

b)

carfilzomib

c)

ixazomib

d)

palbociclib

e)

panobinostat

59.

Compounds chemically related to vitamin A that modulate cell proliferation

a)

Retinoids

b)

Phophatidylinositol 3-kinase (PI3K) & mTOR inhibitors

60.

Important signaling for growth, metabolism and translation

a)

Retinoids

b)

Phophatidylinositol 3-kinase (PI3K) & mTOR inhibitors

61.

Isotretinoin is an example of:

a)

Retinoids

b)

Phophatidylinositol 3-kinase (PI3K) & mTOR inhibitors

62.

Idelalisib and everolimus are examples of:

a)

Retinoids

b)

Phophatidylinositol 3-kinase (PI3K) & mTOR inhibitors